• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Petros Pharmaceuticals Launches U.S. Distribution Of STENDRA Through Collaboration With 23andMe Subsidiary, Lemonaid Health

    5/14/24 9:23:12 AM ET
    $ME
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email

    Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1]

    Please see Important Safety Information and study design below

     

    Get the next $ME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ME
    $PTPI

    CompanyDatePrice TargetRatingAnalyst
    23andMe Holding Co.
    $ME
    11/29/2022$7.00Buy
    Berenberg
    23andMe Holding Co.
    $ME
    9/22/2022$6.00Outperform
    Cowen
    23andMe Holding Co.
    $ME
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    23andMe Holding Co.
    $ME
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    23andMe Holding Co.
    $ME
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    23andMe Holding Co.
    $ME
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    23andMe Holding Co.
    $ME
    8/17/2021$13.00Outperform
    Credit Suisse
    23andMe Holding Co.
    $ME
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    $PTPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/6/26 5:30:07 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/2/26 5:00:51 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/2/26 5:00:36 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    $PTPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

    SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

    3/26/25 6:57:42 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

    Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

    3/23/25 11:08:03 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

    SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

    3/21/25 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    $PTPI
    SEC Filings

    View All

    SEC Form NT 10-K filed by Petros Pharmaceuticals Inc.

    NT 10-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    3/31/26 4:30:12 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.

    SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    2/17/26 10:50:32 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    1/2/26 5:00:44 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    $PTPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on 23andMe with a new price target

    Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

    11/29/22 7:24:54 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on 23andMe with a new price target

    Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

    9/22/22 7:20:18 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on 23andMe Holding with a new price target

    Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

    2/11/22 8:14:04 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    $PTPI
    Financials

    Live finance-specific insights

    View All

    23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

    SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

    11/12/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

    11/7/24 5:54:12 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

    11/7/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    $PTPI
    Leadership Updates

    Live Leadership Updates

    View All

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Oblong Appoints Two New Directors to its Board

    Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

    5/30/23 8:00:00 AM ET
    $OBLG
    $PMCB
    $PTPI
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ME
    $PTPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care